Investors with a lot of money to spend have taken a bearish stance on Biohaven BHVN.
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with BHVN, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 19 options trades for Biohaven.
This isn't normal.
The overall sentiment of these big-money traders is split between 15% bullish and 84%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $33,000, and 18, calls, for a total amount of $1,611,933.
Expected Price Movements
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $20.0 to $45.0 for Biohaven during the past quarter.
Analyzing Volume & Open Interest
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Biohaven's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Biohaven's whale trades within a strike price range from $20.0 to $45.0 in the last 30 days.
Biohaven Option Volume And Open Interest Over Last 30 Days
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| BHVN | CALL | SWEEP | BEARISH | 07/19/24 | $20.00 | $120.0K | 1.3K | 100 |
| BHVN | CALL | TRADE | BULLISH | 07/19/24 | $20.00 | $120.0K | 1.3K | 500 |
| BHVN | CALL | SWEEP | BEARISH | 07/19/24 | $20.00 | $120.0K | 1.3K | 400 |
| BHVN | CALL | TRADE | NEUTRAL | 07/19/24 | $20.00 | $120.0K | 1.3K | 350 |
| BHVN | CALL | TRADE | NEUTRAL | 07/19/24 | $20.00 | $120.0K | 1.3K | 300 |
About Biohaven
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on discovering and developing therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, immunology, and disease-related biology, including rare disorders. Its neuroscience portfolio includes a broad pipeline of drug candidates modulating distinct nervous system targets, including Kv7, glutamate receptors, myostatin, and TRP channels. Its products target diseases such as migraine, depression, bipolar, and schizophrenia.
Where Is Biohaven Standing Right Now?
- Trading volume stands at 1,175,083, with BHVN's price up by 0.77%, positioned at $42.92.
- RSI indicators show the stock to be may be overbought.
- Earnings announcement expected in 73 days.
Expert Opinions on Biohaven
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $50.0.
- An analyst from HC Wainwright & Co. downgraded its action to Buy with a price target of $50.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Biohaven with Benzinga Pro for real-time alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Date of Trade | ticker | Put/Call | Strike Price | DTE | Sentiment |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
